Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA). Expanded access allows patients with a serious or a life-threatening disease or condition access to an investigational drug when no satisfactory approved treatment options are available.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456

Multiple System Atrophy Multiple System Atrophy, Cerebellar Variant Multiple System Atrophy, Parkinson Variant (Disorder) +1 more

COMPLETED EARLY_PHASE1

Study of BHV-3241 in Participants With Multiple System Atrophy

NCT03952806

Multiple System Atrophy

COMPLETED PHASE3

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT04280484

Multiple Sclerosis, Relapsing-Remitting

COMPLETED NA

CorEvitas Multiple Sclerosis (MS) Registry

NCT03291756

Multiple Sclerosis

ENROLLING_BY_INVITATION

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT04886492

Neuromyelitis Optica Spectrum Disorder

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple System Atrophy (MSA)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BHV3241, verdiperstat

BHV3241/Verdiperstat 600mg BID

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. with a diagnosis of probable or possible MSA documented by a physician according to consensus clinical criteria,5 including patients with MSA of either subtype, MSA-P or MSA-C.
2. able to swallow whole tablets without crushing or chewing.
3. with established care with a physician at the specialized MSA center involved in the protocol and will maintain this clinical care throughout the duration of the EAP.
4. not eligible for an ongoing clinical study with verdiperstat and/or an ongoing EAP for MSA

Exclusion Criteria

1. Based on the Physician's judgement, any condition (including history of a clinically significant or unstable medical condition or lab abnormality) that would interfere with the patient's ability to comply with the EAP instructions, visit schedule, requirements and/or procedures, place the patient at unacceptable risk, or confound/interfere with the adequate assessment/interpretation of data; including difficulty swallowing verdiperstat tablets or any other sound medical, psychiatric and/or social reason.
2. Presence of clinically significant thyroid disease despite treatment and/or TSH \>10 mIU/ L at Screening/Baseline, confirmed by repeat.
3. Patient is known to have acute or chronic liver disease that is clinically significant in the Prescriber's judgment
4. First or second dose of COVID-19 vaccination within 7 days of first dose of verdiperstat.

Eligible Sex

ALL

Accepts Healthy Volunteers

No